Introduction {#S1}
============

Despite the advances in modern medicine, some of the major challenges currently confronted in treating cancer patients include the development of therapeutic drug resistance and disease recurrence. Traditional treatments target cancer cells as a means to eradicate tumors and treat the patients. These methods are largely based on the stochastic model---a theory that suggests that cancer cells can arise from a cell that undergoes gene mutations resulting in the acquisition of a highly proliferative state ([@B1], [@B2]). Each progenitor cell bears the mutation and phenotypic profile of the parent cell and is capable of reconstituting a tumor. Several studies have since challenged this theory by demonstrating the existence of a subpopulation of cells called cancer stem cells (CSCs) or tumor-initiating cells, which are typically quiescent but under certain conditions, capable of proliferating to self-renew the CSC population and generate progenitor tumor cells ([@B3], [@B4]). CSCs are resistant to therapies that target rapidly proliferating tumor cells and are primarily responsible for tumor relapse. In the 1990s, the theory of a hierarchical organization within tumors was introduced in acute myeloid leukemia (AML), identifying leukemia-initiating cells *via* their expression of a CD34^++^CD38^−^ phenotype. This hierarchical model postulates that individual tumor cells have distinct mutational profiles and epigenetic modifications contributing to cellular heterogeneity. In the years to follow, researchers have used molecular markers to identify and isolate CSCs of various solid tumors ([@B5]--[@B7]).

Currently, there are more than 40 established CSC markers (Table [1](#T1){ref-type="table"}); however, much controversy surrounds the scientific techniques employed to identify surface markers. Moreover, majority of the markers established for the identification of CSCs were previously described in human embryonic stem cells and/or adult stem cells of normal tissue cells ([@B5], [@B8]). This shared feature may suggest two possibilities: CSCs could originate from genetic alterations in normal stem cells or could be the result of dedifferentiation of mutated cancer cells into stem-like cells. Despite the shared properties, CSCs differ from normal stem cells in that unlike CSCs, cell proliferation is rigidly controlled in normal stem cells ([@B9]). Glycosylation of glycoprotein markers has also been suggested to impact the biological behavior of CSCs ([@B8]). It is important to focus future investigation on the mutations, metabolic phenotype, and other aspects of the microenvironment that distinguish CSCs from normal stem cells.

###### 

Biomarkers reported to characterize CSCs.

  Marker                                Cancers identified                                                                                                                                                                                            Metabolic phenotype                                       Reference
  ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ------------------
  ABCG2                                 HNSCC, retinoblastoma, lung cancer, liver cancer, pancreatic cancer, melanoma                                                                                                                                 Hypoxia induced                                           ([@B10])
                                                                                                                                                                                                                                                                                                                
  Aldehyde dehydrogenase 1-A1/ALDH1A1   Liver, kidney, red blood cells, skeletal muscle, lung, breast, lens, stomach, brain, pancreas, testis, prostate, ovary                                                                                        Converts acetaldehyde to acetate, maintains low ROS       ([@B11])
                                                                                                                                                                                                                                                                                                                
  Alpha-methylacyl-CoA racemase/AMACR   Prostate cancer, gastric cancer, nasopharyngeal cancer, CRC                                                                                                                                                   Facilitates metabolic switch to fatty acid β-oxidation    ([@B12])
                                                                                                                                                                                                                                                                                                                
  CD24                                  Gastric cancer                                                                                                                                                                                                CD24 is a hypoxia-inducible factor                        ([@B13])
                                                                                                                                                                                                                                                                                                                
  CD27                                  Lymphoma, multiple myeloma, B-cell chronic lymphocytic leukemia, renal cell carcinoma, glioblastoma, mesothelioma, HCC, cancers of the pancreas, breast and ovary, CRC, melanoma, neuro-endocrine carcinoma   Not specified                                             ([@B14])
                                                                                                                                                                                                                                                                                                                
  CD44                                  Most epithelial cancers, leukemia                                                                                                                                                                             Promotes glycolysis *via* PKM2 suppression                ([@B15])
                                                                                                                                                                                                                                                                                                                
  CD47                                  AML, ALL, breast cancer, esophageal cancer                                                                                                                                                                    Regulates glycolytic metabolic pathways                   ([@B16])
                                                                                                                                                                                                                                                                                                                
  CD133                                 Brain, breast, CRC, HNSCC, kidney, liver, lung, ovary, pancreas, prostate, stomach, bone/soft tissue, eye, skin                                                                                               Decreased hexokinase II expression, promoted by hypoxia   ([@B17], [@B18])
                                                                                                                                                                                                                                                                                                                
  Connexin 43/GJA1                      Prostate cancer, nasopharyngeal cancer, glioblastoma, HCC                                                                                                                                                     Increased glucose uptake                                  ([@B19])
                                                                                                                                                                                                                                                                                                                
  c-Met                                 HNSCC, breast cancer, thyroid cancer, HCC                                                                                                                                                                     Prevents excessive ROS                                    ([@B20], [@B21])
                                                                                                                                                                                                                                                                                                                
  ErbB2/Her2                            Breast cancer, endometrial cancer, gastric cancer                                                                                                                                                             Promotes aerobic glycolysis                               ([@B22], [@B23])
                                                                                                                                                                                                                                                                                                                
  GLI-1                                 Leukemia, breast cancer, glioma                                                                                                                                                                               Hypoxia induced                                           ([@B24])
                                                                                                                                                                                                                                                                                                                
  GLI-2                                 Leukemia, breast cancer, glioma, osteosarcoma, HCC, pancreatic cancer                                                                                                                                         Hypoxia induced                                           ([@B25])
                                                                                                                                                                                                                                                                                                                
  HIF-2 alpha/EPAS1                     HCC, lung cancer, renal cancer, CRC, melanoma, glioblastoma, gastric cancer                                                                                                                                   Hypoxia induced                                           ([@B26])
                                                                                                                                                                                                                                                                                                                
  IL-3 R alpha/CD123                    AML, pancreatic cancer, non-small cell lung cancer, breast cancer, ovarian cancer                                                                                                                             Promotes glycolytic enzyme activity                       ([@B27], [@B28])
                                                                                                                                                                                                                                                                                                                
  IL-6 R alpha                          Most epithelial cancers                                                                                                                                                                                       Promotes glycogenolysis                                   ([@B29], [@B30])
                                                                                                                                                                                                                                                                                                                
  Integrin alpha 6/CD49f                Prostate cancer, breast cancer, glioblastoma                                                                                                                                                                  Not specified                                             ([@B31], [@B32])
                                                                                                                                                                                                                                                                                                                
  Lgr5/GPR49                            HNSCC, HCC, CRC, ovarian cancer, basal cell carcinoma                                                                                                                                                         Promotes mitochondrial OXPHOS                             ([@B33], [@B34])

*AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; CRC, colorectal carcinoma; HNSCC, head and neck squamous cell carcinoma; HCC, hepatocellular carcinoma; OXPHOS, oxidative phosphorylation; ROS, reactive oxygen species; CSCs, cancer stem cells: PKM2, pyruvate kinase M2*.

Normal stem cells are unique in their ability to self-renew, proliferate, and differentiate into various tissue types, as well as reproduce progeny essential to maintain and repair the organ system in which they are found ([@B35], [@B36]). Embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells have a low mitochondrial DNA copy number, as well as poorly developed mitochondrial morphology and reduced oxidative capacity. On the other hand, glycolytic pathways are highly active in these stem cells. Hypoxia-induced glycolysis in pluripotent stem cells and inhibition of mitochondrial respiration promote stemness, whereas inhibition of glycolysis disrupts proliferation and promotes cell death ([@B37]).

Although CSCs share many of the characteristics of normal stem cells, the differ in that, they contribute to tumor progression, drug resistance, and recurrence ([@B38]). In addition, several reports suggest that CSCs preferentially use glycolysis. However, other reports suggest a propensity for mitochondrial oxidative phosphorylation (OXPHOS) suggesting a possible metabolic plasticity. The aim of this review is to summarize and emphasize some of the key aspects currently known about CSC metabolism and the potential therapeutic targets contributing to cancer progression.

Cellular and Cancer Metabolism {#S2}
==============================

All cells require energy for growth, division, and survival, which they acquire through the absorption of nutrients including glucose that are broken down in a series of metabolic reactions involving glycolysis and cellular respiration through OXPHOS. Under normal physiological conditions, cells rely on both glycolysis and OXPHOS for efficient energy production ([@B39]). The process of glycolysis involves the breakdown of glucose through a series of reactions to produce pyruvate, two molecules of adenosine 5′-triphosphate (ATP), and nicotinamide adenine dinucleotide (NADH). Under normoxic conditions (oxygen is readily available), pyruvate is transported to the mitochondria where it is converted into acetyl coenzyme A. Acetyl CoA enters the tricarboxylic acid cycle to produce high amounts of energy in the form of NADH and flavin adenine dinucleotide (FADH2) molecules. The hydrogen ions from NADH trigger the electron transport chain and generation of up to 32 molecules of ATP through OXPHOS ([@B40], [@B41]).

Since OXPHOS generates more ATP molecules than glycolysis, normal cells rely primarily on OXPHOS as an efficient source of energy. This process, however, is impaired in hypoxic conditions due a dearth in oxygen.

Rapidly proliferating cancer cells outpace angiogenesis resulting in areas of low oxygen. However, increasing evidence suggests that cancer cells engage in glycolysis even in the presence of oxygen ([@B42]). As a result, tumor cells demonstrate enhanced glycolytic production of ATP ([@B43]). Otto Warburg first described this phenomenon now known as the Warburg effect of aerobic glycolysis ([@B41], [@B44], [@B45]). The increased glycolysis was attributed to mitochondrial damage in cancer cells. Subsequent studies found that most cancer cells do not demonstrate mitochondrial damage, but rather suggest that aerobic glycolysis can occur simultaneously to enhance energy production for the maintenance of cancer cell homeostasis ([@B43]). In fact, several studies demonstrate that acceleration of glycolysis provides a source of metabolites and other essential factors required for rapidly dividing cells ([@B41], [@B43], [@B46], [@B47]).

Metabolic Phenotype of CSCs {#S3}
===========================

Due to the highly proliferative, tumorigenic, and drug-resistant properties of CSCs, in-depth investigation of CSC metabolic phenotype has comprised the cornerstone of numerous recent studies. Although metabolic adaptation or plasticity is one of the hallmarks of cancer, the majority of reports suggest that CSCs are primarily glycolytic ([@B48]--[@B55]). However, examination of CSCs isolated from patient tumors suggests that OXPHOS is the main source of energy ([@B56], [@B57]). We describe other multifactorial causes contributing to the apparent differences in CSC metabolism across tumor types in the following sections. Emerging evidence suggests the existence of specific metabolic phenotypes of CSCs based on their location, such as those in actively growing regions of the tumor that have adequate levels of oxygen, hypoxic areas of the tumor, or those in a distant metastatic site summarized in Figure [1](#F1){ref-type="fig"}.

![The schematic represents the metabolic status of cancer stem cells (CSCs) in three broad categories based on the location. CSCs in a normoxic tumor: stemness has been associated with upregulation of glycolytic enzymes in those CSCs that rely on glucose pathway, as well as with dependence on mitochondrial pathway as evidenced by increased mitochondrial mass, membrane potential in CSCs and mitochondrial fatty acid oxidation (FAO) for generation of adenosine 5′-triphosphate and nicotinamide adenine dinucleotide. CSCs in tumor under hypoxia: hypoxia-inducible factor-1α (HIF-1α) promotes upregulation and potentiated activity of several glycolytic proteins, such as transporters (GLUT1, GLUT3) and various isoforms of glycolytic enzymes. CSCs in the metastatic niche: CSCs induced by epithelial-to-mesenchymal transition, have augmented utilization of extracellular catabolites, such as pyruvate, lactate, glutamine, glutamate, alanine, or ketone bodies. In nutrient poor states, quiescent disseminated tumor cells rely on alternative energy sources such as autophagy. The CSC stem cell model of treatment proposes the prevention of recurrence if all CSCs are eliminated.](fonc-08-00203-g001){#F1}

Glycolytic Pathway {#S4}
==================

A number of studies performed in various tumor types, such as glioblastoma, lung cancer, osteosarcoma, breast cancer, ovarian cancer, and colon cancer, suggest that CSCs more strongly favor the glycolytic pathway than other differentiated cancer cells *in vitro* and *in vivo* ([@B58]--[@B62]). Rationale for investigating the role of glycolytic metabolism in CSCs is due to its proposed phenotypic similarity to normal stem cells with self-renewal characteristics. Earlier studies paved the way by illustrating the low activity of mitochondrial respiration in brain tumor CSCs, as well as higher rates of glycolysis in CSCs than other tumor cells ([@B63], [@B64]). Further investigations revealed that upregulation of glycolytic enzymes (GLUT1, HK-1, and PDK-1) and stimulation of glycolysis are necessary for cell immortalization and is sufficient to increase cellular lifespan ([@B65]). Comparing glucose utilization by CSCs and non-CSCs has revealed differentially elevated glucose consumption, lactate synthesis, and ATP content in CSCs, thus suggesting distinct metabolic profiles of CSCs in comparison to non-CSCs ([@B66]--[@B68]). Glycolysis has also been identified as the preferred metabolic pathway of CSCs in nasopharyngeal carcinoma and of tumor-initiating stem-like cells in hepatocellular carcinoma ([@B69], [@B70]). In addition, cellular metabolism is thought to control stemness characteristics; in particular, the glycolytic switch has a causal relation in induced pluripotent stem cell reprogramming and acquisition of pluripotent markers ([@B71]). Reprogramming the metabolic switch from OXPHOS to glycolysis was shown to enhance stemness and CSC properties in CD44^+^CD24^low^EPCAM^+^ cells of basal-like breast cancer by reducing reactive oxygen species (ROS) levels ([@B48]). Glycolysis-driven induction of pluripotency is consistent with the finding that hypoxia maintains the stem cell state and a hypoxic environment promotes the reprogramming process ([@B72]).

Oxphos Pathway {#S5}
==============

Growing evidence suggests mitochondrial oxidative metabolism as the preferred form of energy production in CSCs. Several studies in numerous tumor types, such as CD133^+^ cells of glioblastoma and pancreatic ductal adenocarcinoma, ROS^low^ quiescent leukemia stem cells, lung cancer side population cells, and breast cancer, strongly support an OXPHOS phenotype and less glycolytic profile ([@B49], [@B50], [@B54], [@B73]). In contrast to the non-CSC cancer cells, which mainly utilize glycolysis for energy production, CSCs have an enhanced mitochondrial ROS, higher rates of oxygen consumption, and overall increased mitochondrial function, as evidenced by increased mitochondrial mass and membrane potential ([@B50], [@B52], [@B53], [@B73]--[@B76]). Moreover, this increased mitochondrial bulk in a subpopulation of breast cancer cells induces stem-like characteristics and confers metastatic potential and resistance to DNA damage ([@B77]). In addition, CSCs may depend on mitochondrial fatty acid oxidation (FAO) for the generation of ATP and NADH. A population of isolated ovarian CSCs revealed upregulated expression of genes associated with FAO and OXPHOS ([@B52]). FAO is instrumental in self-renewal processes of hematopoietic stem cells and leukemia-initiating cells, as in the survival of ablation-resistant pancreatic CSCs and survival of epithelial cancer cells subsequent to matrix detachment ([@B78]--[@B80]). An oxidative phenotype confers resistance to treatment modalities and evasion of apoptosis as evidenced by the vastly tumorigenic and chemoresistant metabolism found in hepatocellular CSCs, upon NANOG-induced expression of FAO genes ([@B70]). The powerful antioxidant defense mechanism of CSCs contributes to therapy resistance, by maintaining a significantly lower ROS levels and preserving stemness and tumorigenic properties of CSCs ([@B52], [@B81], [@B82]).

Factors Affecting the Metabolic Status of CSCs {#S6}
==============================================

The reported differences in the metabolic profile of CSCs from various tumor types are due to multifactorial causes. One such explanation is the suggested plasticity of these cells and the potential harvest of them at various stages of differentiation/dedifferentiation during experiments ([@B2]). Another cause may be the lack of uniformity and precision in definition of CSCs and varying techniques utilized to isolate CSCs, such as specific markers, Hoechst staining-based sorting, chemoresistance-based isolation, and reoxygenation sorting post-hypoxic exposure ([@B83]--[@B87]). This is due to a vast heterogeneity of CSCs across various histologic tumor types. Another potential contributing factor that may explain the contradictory results is the contribution of the microenvironment. We broadly distinguish the metabolic status of CSCs in three locations, namely, regions with normoxic tumor, hypoxic tumor, and at metastatic sites (Figure [1](#F1){ref-type="fig"}).

As mentioned in the preceding sections, under normoxic conditions, CSCs can engage in glycolysis and/or OXPHOS. Furthermore, the metabolic status of CSCs can be affected by crosstalk between CSCs and cancer-associated stroma in the microenvironment. For example, cancer-associated fibroblast-secreted metabolites including lactate and ketone bodies drive OXPHOS in cancer cells ([@B88]). The role of cancer-associated stroma in regulating CSC metabolism is unknown.

Similar to embryonic stem cell maintenance, tumor hypoxia promotes the persistence of an undifferentiated, stem cell phenotype ([@B89]). Ductal breast carcinoma cells revert to a stem cell-like phenotype through dedifferentiation under hypoxic conditions ([@B90]). Other studies showed that hypoxic exposure altered gene expression in human neuroblastoma cells toward a neural crest-like, immature profile and caused upregulation of the stem cell surface marker CD-133 in medulloblastoma ([@B90], [@B91]). Under hypoxic conditions, overexpression of hypoxia-inducible factor-1α (HIF-1α) promotes upregulation and potentiated activity of several glycolytic proteins, such as transporters (GLUT1 and GLUT3) and various isoforms of glycolytic enzymes ([@B92]). In addition, HIF-1α regulates pyruvate dehydrogenase kinase 1 levels which facilitate glycolysis in breast CSCs under hypoxic conditions ([@B93]).

Metastatic cancer cells undergo epithelial-to-mesenchymal transition (EMT) upregulating a number of factors associated with a stem-like phenotype. EMT-associated factors including HIF-1α, Wnt, and Snail regulate cellular metabolism ([@B94]). Furthermore, EMT-associated metabolites---glutamine, glutamate, and alanine---as well as high lactate concentrations are associated with poor survival and higher metastatic potential in breast cancers ([@B95], [@B96]). CSCs have augmented utilization of extracellular catabolites, such as pyruvate, lactate, glutamine, glutamate, alanine, or ketone bodies to support OXPHOS ([@B97]--[@B99]). In nutrient poor states, quiescent disseminated tumor cells rely on alternative energy sources such as autophagy, yet metabolic plasticity demonstrated by their ability to produce energy through various pathways is instrumental for metastatic growth and proliferation ([@B100]--[@B102]). Finally, a recent study of metabolic dependencies of non-small cell lung cancers highlighted the significant contribution of the microenvironment as a determinant of the metabolic phenotype of cancer cells, as evidenced by varying profiles *in vitro* and *in vivo* settings. *KRAS*-driven lung cancer cells in mice models showed preferential glutamine utilization *in vitro*, but did not depend on glutamine metabolism *in vivo* ([@B103]).

Targeting Cellular Metabolism {#S7}
=============================

A strong association between tumors with high CSC fractions and recurrence, poorer overall survival, and higher incidence of metastasis, underscores the significant prognostic and therapeutic implications of CSCs ([@B104], [@B105]). Defining characteristics of CSCs such as surface markers, metabolic phenotypes, resistance to chemoradiotherapy, and regulatory factors in microenvironment compile the bulk of therapeutic targets. For instance, CD44, a receptor for hyaluronic acid-mediated motility, is shown to induce CSC attachment to extracellular matrix and cell migration, promoting metastasis and invasion ([@B106]). Treatment of breast, colon, esophageal, gastric, lung, and ovarian cancers overexpressing CD44, with ONCOFID^TM^-S which is a conjugate of hyaluron and chemotherapeutic agent SN38 (7-ethyl-10-hydroxycamptothecin, active metabolite of CPT-11) revealed a strong *in vitro* anti-proliferative activity ([@B107], [@B108]). In addition, use of anti-CD44 antibodies H90 and A3D8 inhibited proliferation and induced apoptosis, by promoting the differentiation of AML blasts ([@B108]--[@B111]). Finally, CD44 interacts with pyruvate kinase M2 (PKM2), enhancing the glycolytic profile of cancer cells deficient in p53 or exposed to hypoxia. Subsequent ablation of CD44 led to inhibition of glycolysis, increase in ROS and enhancement of chemotherapeutic drug effect in these cancer cells ([@B110]). Therefore, preferentially targeting of identified CSC markers, such as CD44, can be utilized for an effective cytotoxic drug delivery. In addition, inhibition of glycolysis can be achieved by targeting various glycolytic enzymes, transporters, and other complex regulators, such as GLUT 1--4, hexokinase, PKM2, and lactate dehydrogenase A ([@B111]--[@B113]).

Previously discussed evidence for OXPHOS dependence of CSCs in numerous cancer lines proposes mitochondrial metabolism to be a potential target for an effective elimination of CSCs. Inhibition of the OXPHOS pathway reduces sphere formation and tumor formation potential demonstrating vulnerability of CSC to mitochondria-targeted therapies ([@B54], [@B114], [@B115]). Pharmacological agents targeting CSCs through inhibition of mitochondrial biogenesis and OXPHOS are currently under investigation for cancer treatment. Several FDA-approved compounds known to inhibit mitochondrial function have been reported to achieve a more effective eradication of CSCs. Salinomycin, erythromycins, tetracyclines, and glycylcyclines are some of the approved agents to have already demonstrated efficacy in eradicating CSCs *via* reduction of stemness properties ([@B115]--[@B118]). Metformin, an inhibitor of OXPHOS complex I, has demonstrated anti-tumoral activity by reducing mammosphere formation, delaying *in vivo* tumor growth, and inducing apoptosis in pancreatic CSCs unable to switch to glycolysis ([@B54], [@B119], [@B120]). However, emergence of a small subset of resistant CSCs with an intermediate glycolytic/OXPHOS phenotype could be prevented/reversed by utilizing a mitochondrial ROS inducer such as menadione ([@B54]). Dual mechanism of menadione inhibition of Complex I and induction of mitochondrial ROS points out the superior efficacy of multi-modal targeted therapy. Studies have shown that inhibition of mitochondrial respiration not only induces apoptosis in pancreatic CSCs with OXPHOS phenotype but also effectively eliminates primarily glycolytic breast and nasopharyngeal CSCs ([@B53], [@B54], [@B121]). These data highlight the extended role of mitochondria beyond energy production in CSCs, such as acquiring metabolites from glutamine *via* reductive carboxylation to support growth in tumor cells with defective mitochondria ([@B122]). A novel compound 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) has been shown to inhibit pancreatic cancer growth by targeting a CSC marker, doublecortin and CaM kinase-like-1 (DCLK-1) ([@B59], [@B66], [@B123]). However, the role of DCLK-1 and the impact of DiFiD on CSC metabolism have not been studied.

Evident from the data reviewed, the CSC phenotype varies between cancer subtypes and among populations of the same subtypes. Preferred energy-producing metabolic pathways depend on various factors, including metastatic site highlighting vast metabolic variability and patterns ([@B124]). In addition to studies supporting metabolic plasticity, simultaneous enhancement of glycolysis and OXPHOS pathways was observed in highly metastatic breast cancer cell lines relative to non-metastatic cell lines ([@B49], [@B124]). Consequently, dual inhibition of glycolytic and mitochondrial energy pathways has proven to be effective against tumor growth in a number of preclinical cancer models ([@B125]). One such study elegantly demonstrated sarcoma cells to be twofold to fivefold more sensitive than normal cells to dual inhibition of glycolysis with 2-deoxyglucose and OXPHOS with oligomycin or metformin ([@B126]). Therefore, dual inhibition of metabolic pathways may be a superior approach to eradicating heterogeneous CSCs rather than singularly targeting glycolysis or OXPHOS pathways. Finally, other factors directly affecting metabolic status of CSCs may represent potential targets for pharmacological treatments. These developments may include promoting CSC differentiation, targeting complex interactions within the microenvironment, and disrupting cellular communications in the CSC niche to interfere with CSC growth, resistance, and metastasis ([@B97], [@B127]--[@B130]).

Conclusion {#S8}
==========

Substantial evidence suggests that the CSCs are pluripotent, self-renewing, "original cells" of a tumor capable of differentiation into more specialized cancer cell types. CSCs are responsible for tumor formation, differentiation, maintenance, spread, and recurrence, making them an attractive therapeutic target for a potential permanent cure or long-term disease-free survival ([@B127], [@B131]). Regardless of the controversy about the metabolic phenotype of CSCs, metabolism is not only a key player but also a regulatory instigator of stemness.

Metabolic singularities that distinguish CSCs need to be further investigated, as they offer a great potential for developing improved treatments to eradicate them. In particular, streamlining and standardization of CSC identification methods is important. Development of CSC marker combinations would contribute to better delineation of CSCs from non-CSC cancer cells and normal stem cells. Interactions between CSCs and their microenvironment also provide a fertile ground for advance investigations. Chronicity and causality of these complex interactions needs to be established. Moving forward, CSC metabolic pathways and principal players of metabolism comprise potential therapeutic targets with a great promise for improved cancer treatments.
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